In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Dysregulation of insulin levels in Chagas heart disease is associated with altered adipocytokine levels

Session Poster Session 2

Speaker Assistant Professor Fabio Fernandes

Congress : ESC Congress 2018

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Chagas Disease
  • Session type : Poster Session
  • FP Number : P1602

Authors : A Dabarian (Sao Paulo,BR), C Mady (Sao Paulo,BR), JMB Ferreira (Sao Paulo,BR), B Ianni (Sao Paulo,BR), VT Hotta (Sao Paulo,BR), FJA Ramires (Sao Paulo,BR), HF Lopes (Sao Paulo,BR), F Fernandes (Sao Paulo,BR)


A. Dabarian1 , C. Mady1 , J.M.B. Ferreira1 , B. Ianni1 , V.T. Hotta1 , F.J.A. Ramires1 , H.F. Lopes1 , F. Fernandes1 , 1Heart Institute (InCor) - University of Sao Paulo Faculty of Medicine Clinics Hospital - Sao Paulo - Brazil ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 312

Background: Metabolic, inflammatory, and autonomic nervous system dysfunctions are present in patients with heart failure (HF). However, whether these changes are due to left ventricular dysfunction or heart failure is unknown.

Methods: We evaluated metabolism and inflammatory activity in patients with idiopathic dilated cardiomyopathy (IDC) and chagasic cardiomyopathy (CHG) and their correlation with the autonomic nervous system (ANS). Forty-six patients were divided into 3 groups: IDC, CHG, and control (CG). All patients underwent anthropometric measurements. Levels of adiponectin, leptin, insulin, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) were assayed in serum samples using ELISA. ANS was assessed by heart rate variability in time and frequency domains on a 24-hour Holter monitor. High-frequency (HFr) component values were used to estimate parasympathetic activity, and low-frequency (LFr) component values were used for sympathetic activity. Analyzes were made of the correlations of each of the metabolic parameters (insulin, leptin, and adiponectin) with the inflammatory cytokines (interleukin-6 and TNF-alpha) and with ANS assessment measurements.

Results: No differences were noted between groups regarding blood glucose levels, total cholesterol, leptin, and adiponectin. Insulin levels were lower in CHG 5.4±3.3 μU/mL compared with that in CG 8.0±4.9 μU/mL and IDC 9.9±5.0 μU/mL (p=0.007). Levels of interleukin-6 and tumor necrosis factor-alpha were also higher in CHG compared with that in the other groups. Insulin was positively associated with leptin (r=0.579; p=0.024), LFr/HFr ratio (r=0.562; p=0.029), and with the LFr component (r=0.562; p=0.029) in CHG. Insulin levels were negatively associated with adiponectin (r = -0.603; p=0.017). The addition of an adiponectin unit reduced average insulin by 0.332 ug/mL. A decrease was noted in insulin levels in CHG compared with that in IDC and CG. Insulin levels were associated with ANS parameters and adiponectin.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are